Inhibition of HDAC6-dependent carcinogenesis: Emerging, new therapeutic options besides belinostat

International Journal of Cancer

Volumn 124, Issue 2, 2009, Pages 509-

  Kapoor, Shailendra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; BELINOSTAT; BORTEZOMIB; CARBONIC ACID; GELDANAMYCIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KD 5170; PACLITAXEL; TRITHIOCARBONATE DERIVATIVE; TUBACIN; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE;

CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; DOWN REGULATION; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; LETTER; LEUKEMIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T CELL LYMPHOMA; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; MALE; METHODOLOGY; NOTE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; PROSTATIC NEOPLASMS;

EID: 58249094713     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23975     Document Type: Letter

References (9)

1. Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 2008;122:1400.
2. S J Haggarty, Domain-selective small-molecule inhibitor of histone deacetylase 6(HDAC 6)-mediated tubulin deacetylation. Proc Natl Acad Sci 2003;100:4389-94.
3. Dehmel F, Weinbrenner S, Julius H, Ciossek T, Maier T, Stengel T, Fettis K, Burkhardt C, Wieland H, Beckers T. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles. J Med Chem 2008;51:3985-4001.
4. Itoh Y, Suzuki T, Kouketsu A, Suzuki N, Maeda S, Yoshida M, Nakagawa H, Miyata N. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J Med Chem 2007;50:5425-38.
5. Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y,
6. Anzola JV, et al. KD5170, a novel mercaptoketone-based his tone deacetylase inhibitor that exhibits broad spectrum anti tumor activity in vitro and in vivo. Mol Cancer Ther 2008;7:1054-65.
7. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD. Phase II trial of oral vorinostat (suber oylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19:964-9.
8. Kamemura K, Ito A, Shimazu T, Matsuyama A, Maeda S, Yao TP, Horinouchi S, Khochbin S, Yoshida M. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. Biochem Biophys Res Commun 2008;374:84-9.
9. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112:1886-93.